CYP2C19

GENETIC2 trials

Sponsors

Gyeongsang National University Hospital, Beijing Anzhen Hospital

Conditions

Antiplatelet TherapyCYP2C19 PolymorphismMyocardial Infarction

Phase 4

Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism

CompletedNCT00915733

Gyeongsang National University HospitalMyocardial Infarction

Start: 2009-05-31End: 2009-11-30Updated: 2009-11-10

Unknown Phase

The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

Beijing Anzhen HospitalAntiplatelet Therapy, CYP2C19 Polymorphism

Start: 2018-12-01End: 2021-09-30Target: 12000Updated: 2020-12-08

Related Papers

Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

2012-04-016 citations

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

2011-04-0142 citations

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.

2010-07-0155 citations